MAPK3 and non-small cell lung carcinoma: As expected, we show that HCC827 (ex19del)-NSCLC cells are susceptible to the TKI erlotinib, as indicated by reduced phospho-ERK1/2 signaling upon erlotinib treatment, whereas H1975 cells harboring the T790M mutation are resistant to erlotinib (Fig. 6c).